AU2005277343B2 - Extended treatment of multiple sclerosis - Google Patents

Extended treatment of multiple sclerosis Download PDF

Info

Publication number
AU2005277343B2
AU2005277343B2 AU2005277343A AU2005277343A AU2005277343B2 AU 2005277343 B2 AU2005277343 B2 AU 2005277343B2 AU 2005277343 A AU2005277343 A AU 2005277343A AU 2005277343 A AU2005277343 A AU 2005277343A AU 2005277343 B2 AU2005277343 B2 AU 2005277343B2
Authority
AU
Australia
Prior art keywords
vla
months
binding antibody
antibody
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2005277343A
Other languages
English (en)
Other versions
AU2005277343A1 (en
Inventor
Frances Lynn
Michael Panzara
Martin Toal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen MA Inc filed Critical Biogen MA Inc
Publication of AU2005277343A1 publication Critical patent/AU2005277343A1/en
Application granted granted Critical
Publication of AU2005277343B2 publication Critical patent/AU2005277343B2/en
Priority to AU2011232775A priority Critical patent/AU2011232775B2/en
Assigned to BIOGEN MA INC. reassignment BIOGEN MA INC. Request to Amend Deed and Register Assignors: BIOGEN IDEC MA INC.
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preliminary Treatment Of Fibers (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heat Treatment Of Articles (AREA)
AU2005277343A 2004-08-20 2005-08-18 Extended treatment of multiple sclerosis Expired AU2005277343B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2011232775A AU2011232775B2 (en) 2004-08-20 2011-10-06 Extended Treatment of Multiple Sclerosis

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US60346804P 2004-08-20 2004-08-20
US60347004P 2004-08-20 2004-08-20
US60349504P 2004-08-20 2004-08-20
US60/603,495 2004-08-20
US60/603,468 2004-08-20
US60/603,470 2004-08-20
US61602304P 2004-10-05 2004-10-05
US60/616,023 2004-10-05
PCT/US2005/029407 WO2006023651A2 (en) 2004-08-20 2005-08-18 Extended treatment of multiple sclerosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2011232775A Division AU2011232775B2 (en) 2004-08-20 2011-10-06 Extended Treatment of Multiple Sclerosis

Publications (2)

Publication Number Publication Date
AU2005277343A1 AU2005277343A1 (en) 2006-03-02
AU2005277343B2 true AU2005277343B2 (en) 2011-07-07

Family

ID=35968170

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005277343A Expired AU2005277343B2 (en) 2004-08-20 2005-08-18 Extended treatment of multiple sclerosis

Country Status (6)

Country Link
US (5) US20090010926A1 (enExample)
EP (2) EP1789086A4 (enExample)
JP (4) JP2008510714A (enExample)
AU (1) AU2005277343B2 (enExample)
CA (2) CA2478458A1 (enExample)
WO (4) WO2006023651A2 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ556105A (en) * 2004-12-03 2009-12-24 Biogen Idec Inc Delaying or preventing onset of multiple sclerosis
JP4871355B2 (ja) 2005-05-12 2012-02-08 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 無線メッシュネットワークのための分散型学習方法
ES2752137T3 (es) 2006-02-28 2020-04-03 Biogen Ma Inc Métodos para tratar enfermedades inflamatorias y autoinmunes con natalizumab
CA2644110A1 (en) * 2006-03-03 2007-09-13 Elan Pharmaceuticals, Inc. Methods of treating inflammatory and autoimmune diseases with natalizumab
CA2714335A1 (en) * 2007-02-20 2008-08-28 Merrimack Pharmaceuticals, Inc. Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
AR067011A1 (es) 2007-06-14 2009-09-30 Biogen Idec Inc Formulaciones de anticuerpos
US11287423B2 (en) 2010-01-11 2022-03-29 Biogen Ma Inc. Assay for JC virus antibodies
NZ600681A (en) 2010-01-11 2014-10-31 Biogen Idec Inc Assay for jc virus antibodies
US20140161794A1 (en) 2010-04-16 2014-06-12 Biogen Idec Ma Inc. Anti-vla-4 antibodies
EP2600901B1 (en) 2010-08-06 2019-03-27 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
MX2013003681A (es) 2010-10-01 2013-11-20 Moderna Therapeutics Inc Ácidos nucleicos manipulados y métodos de uso de los mismos.
WO2012135805A2 (en) 2011-03-31 2012-10-04 modeRNA Therapeutics Delivery and formulation of engineered nucleic acids
PH12013502443A1 (en) * 2011-05-26 2019-03-22 Biogen Ma Inc Methods of treating multiple sclerosis and preserving and/or increasing myelin content
EP3575792B1 (en) 2011-05-31 2022-11-30 Biogen MA Inc. Method of assessing risk of pml
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9428535B2 (en) 2011-10-03 2016-08-30 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
SMT202200355T1 (it) 2011-12-16 2022-11-18 Modernatx Inc Composizioni di mrna modificato
JP5711167B2 (ja) 2012-02-22 2015-04-30 三ツ星ベルト株式会社 アラミド心線及び伝動ベルト
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
EP2834260A4 (en) 2012-04-02 2016-08-10 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES FOR THE PREPARATION OF MEMBRANE PROTEINS
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
EP2922554B1 (en) 2012-11-26 2022-02-23 ModernaTX, Inc. Terminally modified rna
JO3529B1 (ar) 2013-02-08 2020-07-05 Amgen Res Munich Gmbh مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
HK1216546A1 (zh) 2013-05-28 2016-11-18 Biogen Ma Inc. 评估pml风险的方法
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
JP2016538829A (ja) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低密度リポタンパク質受容体をコードするポリヌクレオチド
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
EP3501510B1 (en) 2014-02-28 2020-07-01 Banner Life Sciences LLC Controlled release enteric soft capsules of fumarate esters
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
MA41785A (fr) 2015-03-20 2018-01-23 Biogen Ma Inc Procédés et compositions pour l'administration intraveineuse de fumarates pour le traitement de maladies neurologiques
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
JP7193448B2 (ja) 2016-08-31 2022-12-20 マピ ファーマ リミテッド 酢酸グラチラマーを含むデポシステム
IL316573A (en) 2017-03-26 2024-12-01 Mapi Pharma Ltd Storage systems containing glatiramer acetate for the treatment of multiple sclerosis
US12037398B2 (en) 2018-06-04 2024-07-16 Biogen Ma Inc. Anti-VLA-4 antibodies having reduced effector function
US11903918B2 (en) 2020-01-10 2024-02-20 Banner Life Sciences Llc Fumarate ester dosage forms with enhanced gastrointestinal tolerability

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009169A1 (en) * 2002-02-25 2004-01-15 Julie Taylor Administration of agents for the treatment of inflammation

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) * 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) * 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4475196A (en) * 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) * 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) * 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) * 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) * 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
NZ215865A (en) * 1985-04-22 1988-10-28 Commw Serum Lab Commission Method of determining the active site of a receptor-binding analogue
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
HU196394B (en) * 1986-06-27 1988-11-28 Richter Gedeon Vegyeszet Process for preparing 2-halogenated ergoline derivatives
DE3883899T3 (de) * 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) * 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5217870A (en) * 1989-04-28 1993-06-08 Biogen, Inc. Monoclonal antibodies against CDX
US6307025B1 (en) * 1989-04-28 2001-10-23 Biogen, Inc. VCAM fusion proteins and DNA coding therefor
US5272263A (en) * 1989-04-28 1993-12-21 Biogen, Inc. DNA sequences encoding vascular cell adhesion molecules (VCAMS)
US5260210A (en) * 1989-09-27 1993-11-09 Rubin Lee L Blood-brain barrier model
US6033665A (en) * 1989-09-27 2000-03-07 Elan Pharmaceuticals, Inc. Compositions and methods for modulating leukocyte adhesion to brain endothelial cells
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) * 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DK0590058T3 (da) * 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
US5871734A (en) * 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
US5932214A (en) * 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
US5383851A (en) * 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
WO1994011027A1 (en) * 1992-11-13 1994-05-26 Board Of Regents Of University Of Washington Peripheralization of hematopoietic stem cells
ATE182625T1 (de) * 1993-01-12 1999-08-15 Biogen Inc Rekombinante anti-vla4 antikörpermoleküle
ATE161730T1 (de) 1993-02-09 1998-01-15 Biogen Inc Antikörper zur behandlung von insulinabhängigen diabetes
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6432404B1 (en) * 1993-12-23 2002-08-13 Icos Corporation Methods of inhibiting locomotor damage following spinal cord injury with α D-specific antibodies
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US5672622A (en) * 1994-04-21 1997-09-30 Berlex Laboratories, Inc. Treatment of multiple sclerosis
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE19541844C1 (de) * 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
EP2305027B1 (en) * 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
US6890526B2 (en) * 1997-05-06 2005-05-10 Vanderbilt University Methods and reagents for the treatment of multiple sclerosis
US6153653A (en) * 1997-11-26 2000-11-28 Protarga, Inc. Choline compositions and uses thereof
JP2001527040A (ja) * 1997-12-30 2001-12-25 バイオアブソーバブル コンセプツ，インコーポレイティド 神経系の脳血管性疾患を治療、抑制及び防止するためのテトラサイクリン及び／又はテトラサイクリン誘導体
US20040107368A1 (en) * 1998-06-04 2004-06-03 Z4 Technologies, Inc. Method for digital rights management including self activating/self authentication software
US7232830B2 (en) * 1998-06-26 2007-06-19 Elaine A Delack Method for treatment of neurodegenerative diseases and effects of aging
US6355623B2 (en) * 1998-09-24 2002-03-12 Hopital-Sainte-Justine Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage
US7194092B1 (en) * 1998-10-26 2007-03-20 Microsoft Corporation Key-based secure storage
DE19853487A1 (de) * 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
AU767066B2 (en) * 1999-03-03 2003-10-30 Curis, Inc. Methods of modulating lipid metabolism and storage
WO2001045725A2 (en) * 1999-12-23 2001-06-28 Ancile Pharmaceuticals, Inc. Treatment for inflammatory bowel disease (ibd) and related conditions
EP2258834B1 (en) * 2000-03-31 2015-09-23 The Scripps Research Institute Human aminoacyl-tRNA synthetase polypeptides useful for the regulation of angiogenesis
US8288322B2 (en) 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
AU2003284246A1 (en) * 2002-10-16 2004-05-04 Samuel F. Hunter Method for treatment of demyelinating central nervous system disease using gm-csf
RU2412721C2 (ru) * 2003-01-24 2011-02-27 Элан Фармасьютикалз Инк. Применение ремиелинизирующего средства для стимуляции нервных клеток при демиелинизирующем заболевании
HUE051878T2 (hu) * 2003-02-10 2021-03-29 Biogen Ma Inc Immunglobulin készítmény és annak elõállítási módszere
BRPI0508762A (pt) * 2004-04-16 2007-08-14 Genentech Inc método de aumento do esgotamento de células b em mamìferos, método de aumento da eficácia do esgotamento de células b, método de tratamento de malignidade ou neoplasma de células b, método de alìvio de disfunção autoimunológica regulada por células b, método de esgotamento das células b e composição
PT1784426E (pt) * 2004-09-03 2012-03-06 Genentech Inc Antagonistas humanizados anti-beta7 e suas utilizações
KR20080021085A (ko) * 2005-06-09 2008-03-06 유씨비 파마, 에스.에이. 2，6 퀴놀리닐 유도체, 이들을 제조하는 방법 및 이들의약제로서의 용도
WO2007008943A2 (en) * 2005-07-08 2007-01-18 Xencor, Inc. Optimized anti-ep-cam antibodies
WO2008157282A1 (en) * 2007-06-18 2008-12-24 Genentech, Inc. Biological markers predictive of rheumatoid arthritis response to b-cell antagonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009169A1 (en) * 2002-02-25 2004-01-15 Julie Taylor Administration of agents for the treatment of inflammation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MILLER DAVID H et al. New England Journal of Medicine. 2003. 248(1): 15-23 *
MILLER DH. Journal of Neurochemistry. 85 (Supplemental 1): 96; C15-04 *
RUDICK RICHARD A et al. Neurology. 2003. 60(5 Supplement 1): A479 *

Also Published As

Publication number Publication date
US20090010926A1 (en) 2009-01-08
WO2006023649A2 (en) 2006-03-02
WO2006023649A3 (en) 2006-06-22
EP2783701A3 (en) 2014-12-17
WO2006036371A3 (en) 2006-12-21
WO2006023651A2 (en) 2006-03-02
JP2012067139A (ja) 2012-04-05
EP1789086A2 (en) 2007-05-30
JP2015052022A (ja) 2015-03-19
US20150175703A1 (en) 2015-06-25
CA2478458A1 (en) 2006-02-20
US20120276048A1 (en) 2012-11-01
EP1789086A4 (en) 2009-01-14
AU2005277343A1 (en) 2006-03-02
CA2577188A1 (en) 2006-03-02
US20080260728A1 (en) 2008-10-23
EP2783701A2 (en) 2014-10-01
JP2008510714A (ja) 2008-04-10
WO2006023629A2 (en) 2006-03-02
US20150030590A1 (en) 2015-01-29
WO2006023651A3 (en) 2006-09-21
WO2006036371A2 (en) 2006-04-06
WO2006023629A3 (en) 2006-09-28
JP2012036225A (ja) 2012-02-23

Similar Documents

Publication Publication Date Title
AU2005277343B2 (en) Extended treatment of multiple sclerosis
US11571477B2 (en) Anti-VLA-4 antibodies
US9533044B2 (en) Methods of treating inflammatory disorders using high concentration natalizumab compositions
HK1203055A1 (en) Treatment for multiple sclerosis
AU2011232775B2 (en) Extended Treatment of Multiple Sclerosis
AU2012202575B2 (en) Treatment for Multiple Sclerosis
CA2478455A1 (en) Treatment of severe multiple sclerosis
HK40076026A (en) Anti-vla-4 antibodies
CA2478456A1 (en) Combination therapy
HK40005884B (en) Anti-vla-4 antibodies
HK1242339B (en) Anti-vla-4 antibodies
HK1242339A1 (en) Anti-vla-4 antibodies
HK1174931B (en) Anti-vla-4 antibodies
HK1174931A (en) Anti-vla-4 antibodies

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired